Statement



Roche signs up to the Science Based Targets initiative and the Sustainable Markets Initiative to further deepen the commitment to climate actions

Basel, 17 November 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it is committing to the Science Based Targets initiative (SBTi) and the Sustainable Markets Initiative (SMI) to achieve net zero for scope 1, 2 and 3 greenhouse gas emissions.

Since 2004, Roche has been implementing carbon dioxide reduction measures that have led to a combined decrease of over 70% in tons of carbon dioxide per employee. By committing to achieve net-zero in line with the external framework provided by SBTi, Roche continues its successful carbon reduction journey on Scope 1 and 2 (own operations and purchased energy) and extends its reduction strategy to the up- and downstream value chain (Scope 3). Roche is committed to reducing emissions within its value chain and to invest into additional climate mitigation for any residual emissions to reach net zero across all emission scopes.

Recognising that this requires a broader effort, Roche has also joined the SMI Health Systems Taskforce to address emissions across supply chains, patient care pathways, and clinical trials. Specific actions are published <u>here</u>.

"Sustainability is part of Roche's DNA. We have set clear targets and are working hard to truly reduce our emissions percent by percent, year after year. But it takes a broader effort to tackle the climate crisis. And how we do this will ultimately decide our future", says Severin Schwan, Chief Executive Officer. "This is why sector-level initiatives like this one are critical to jointly find and implement concrete solutions at scale."

Sustainability at Roche

For 125 years, sustainability has been an integral part of Roche's business. Roche follows a holistic approach when managing sustainability and integrates the three dimensions of sustainability:

- Society: how we contribute to a better tomorrow for all
- Environment: how we minimise our impact on nature
- Economy: how we invest in medical advances, create jobs and ensure livelihoods

Roche makes its biggest contribution to society by improving healthcare provision. It does so by developing innovative treatments across major disease areas and medical assays, digital solutions and services helping people live healthier lives.



Roche is aware that this cannot be done alone. The company knows that the key to creating sustainable value and growth lies in partnering with stakeholders and engaging in open, constructive dialogue. By doing so, Roche generates value for society and achieves sustainable economic growth for the company.

Further information on our activities across sustainability areas can be found here:

www.roche.com/sustainability

About the Science Based Target Initiative (SBTi)

The Science Based Targets initiative (SBTi) drives ambitious climate action in the private sector by enabling organizations to set science-based emissions reduction targets.

The SBTi is a partnership between CDP, the United Nations Global Compact, World Resources Institute (WRI) and the World Wide Fund for Nature (WWF). The SBTi is the lead partner of the <u>Business Ambition for 1.5°C campaign</u> - an urgent call to action from a <u>global coalition</u> of UN agencies, business and industry leaders, mobilizing companies to set net-zero science-based targets in line with a 1.5°C future.

About the SMI

The Sustainable Markets Initiative (SMI) started in 2020 at the World Economic Forum Annual Meeting at Davos. It was launched by His Majesty King Charles III in his former role as His Royal Highness The Prince of Wales. The SMI aims to lead the transition to a sustainable future by convening public and private sector leaders to align economic value with social and environmental sustainability.

About the SMI Health Systems Taskforce

The SMI Health Systems Taskforce launched at the 26th United Nations Climate Change Conference (COP26) with the central aim of accelerating the delivery of net zero, patient-centric healthcare systems that improve individual, societal, and planetary health. The public-private partnership brings together CEOs and leaders from AstraZeneca, GSK, Merck, Novo Nordisk, Roche, Samsung Biologics, Sanofi, the Karolinska Institutet, National Health Service England, the Sustainable Healthcare Coalition, UNICEF, the University of Pavia, and the World Health Organization (WHO).

About Roche

Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how



healthcare is delivered to have an even greater impact. To provide the best care for each person, we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

In recognising our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Roche Group Media Relations

Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Hans Trees, PhD Karsten Kleine

Phone: +41 79 407 72 58 Phone: +41 79 461 86 83

Nina Mählitz Nathalie Altermatt

Phone: +41 79 327 54 74 Phone: +41 79 771 05 25

Dr. Barbara von Schnurbein Sileia Urech

Phone: +41 79 699 97 44 Phone: +41 79 935 81 48